Publications database

In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N -phenyl- N -[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that sufficient information...

This summary was prepared in cooperation with the Moroccan Observatory on Drugs and Addiction , in the framework of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) technical cooperation project...

Methodological report showing the methods and definitions of TDI (treatment demand indicator) data reported to the EMCDDA in 2014. TDI is one of the EMCDDA's key epidemiological indicators.

Cocaine is Europe’s most commonly used illicit stimulant drug, with about 3.6 million adults (aged 15–64) estimated to have used it in the last year. It is the second most seized drug...

Comorbidity of substance use and mental health disorders refers to the co-occurrence of a substance use disorder and another mental health disorder in the same individual. In Europe, the presence of psychiatric...

This brochure provides an overview of the 2016 European Drug Report package and includes brief summaries of the four new additions to the Perspectives on drugs (PODs) series.

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with...

Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common infectious disease among injecting drug users in Europe today.In this analysis, the EMCDDA looks at...

The number and diversity of new psychoactive substances reported in Europe in recent years represents a major challenge for Europe’s policymakers. This analysis looks at countries’ legal responses to the new drugs...

Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate is increasing on the legalisation...